Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.49 |
| ▸ | CDK9 | P50750 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618155 | 0.80 | TGFBR1 (0.71) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL16968469 | 0.78 | CDK8 (0.59) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL30668749 | 0.77 | TGFBR1 (0.51) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL2241248 | 0.77 | TGFBR1 (0.51) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL29946359 | 0.77 | AURKB (0.57) | CDK8CDK2MAP4K4PRKACAGSK3B | |
| SCHEMBL858198 | 0.77 | AURKB (0.57) | CDK8CDK2MAP4K4PRKACAGSK3B | |
| SCHEMBL858166 | 0.76 | MAP3K5 (0.54) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL30849544 | 0.76 | CDK8 (0.53) | CDK8TGFBR1PDPK1IKBKEPIM1 | |
| SCHEMBL13888070 | 0.76 | CDC7 (0.53) | CDK8TGFBR1PDPK1IKBKECDC7 | |
| SCHEMBL1050911 | 0.75 | TGFBR1 (0.60) | CDK8TGFBR1PDPK1IKBKECDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| CN-1315827-C | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2007-05-16 | — | — | CN | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1668620-A | 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-09-14 | — | — | CN | disclosed |
| CN-1659166-A | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CDK8 185/4885TGFBR1 2796/4885PDPK1 26/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885TGFBR1 4446/4885PDPK1 47/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885TGFBR1 4446/4885PDPK1 47/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885TGFBR1 4446/4885PDPK1 47/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885TGFBR1 4446/4885PDPK1 47/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885TGFBR1 4446/4885PDPK1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.